Fidelity Management & Research Co has recently announced that it has increased stake in Seres Therapeutics Inc. (NASDAQ:MCRB) by 0.05%. After grabbing 18.61 million shares, the institutional investor is now in possession of 9521.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 15.00% having worth around $164.89 million. Moreover, Federated Global Investment Manag increased its share by 2.84 million to have a control over 18.33 million shares. And Janus Henderson Investors US LLC raised its holdings to 5.79 million shares by acquiring 11.15 million shares or 8.99% of the stake.
Seres Therapeutics Inc. (MCRB) concluded trading on 11/23/22 at a closing price of $7.06, with 0.48 million shares of worth about $3.37 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 134.55% during that period and on Wednesday the price saw a gain of about 6.33%. Currently the company’s common shares owned by public are about 122.53M shares, out of which, 116.29M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 8 analysts are covering the MCRB stock and their offered price forecasts bring an average price target of $12.86. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $25.00 and could fall to a lowest price of $4.00. The stock’s current price level is 45.1% above of average price target set by the analysts, while a rise to estimated low would result in loss of -76.5% for the stock. However, touching the estimated high of $25.00 would mean a gain of 71.76% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 16 times over the past 12 months. They bought 9,281,933 shares in 15 of the transactions. In 1 selling transactions, insiders dumped 5,012 shares.
Federated Hermes Kaufmann Fund, Federated Hermes Kaufmann Small C, and Fidelity Growth Company Fund are the top 3 mutual funds which are holding stakes in Seres Therapeutics Inc. Federated Hermes Kaufmann Fund is currently holding 11.99 million shares of worth totaling $106.23 million. The company recently came buying 6.18 million shares which brought its stake up to 9.66% of the company’s outstanding shares. Fidelity Growth Company Fund, after buying 5.97 million shares, have now control over 4.81% of the stake in the company. It holds 0.0 shares of worth $52.91 million.
However, the stock later moved at a day high price of 7.11, or with a gain of 6.33%. Stock saw a price change of 3.07% in past 5 days and over the past one month there was a price change of 22.36%. Year-to-date (YTD), MCRB shares are showing a performance of -15.25% which decreased to -26.38% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.50 but also hit the highest price of $11.69 during that period. The average intraday trading volume for Seres Therapeutics Inc. shares is 999.89K. The stock is currently trading -5.70% below its 20-day simple moving average (SMA20), while that difference is up 2.09% for SMA50 and it goes to 24.38% higher than SMA200.
Fidelity Management & Research Co acquired 18.61 million shares of Seres Therapeutics Inc. having value of about $164.89 million. Data submitted at the U.S SEC by Fidelity Management & Research Co revealed that the firm now holds 9521.0 shares in the company valued at close to $67218.26, or have control over 0.05% stake in the company. Seres Therapeutics Inc. (NASDAQ: MCRB) currently have 122.53M outstanding shares and institutions hold larger chunk of about 85.80% of that. Holding of mutual funds in the company is about 23.32% while other institutional holders and individual stake holders have control over 42.70% and 18.38% of the stake respectively.
The stock has a current market capitalization of $864.14M and its 3Y-monthly beta is at 2.78. It has posted earnings per share of -$2.35 in the same period. It has Quick Ratio of 3.00 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MCRB, volatility over the week remained 5.37% while standing at 9.62% over the month.
Analysts are in expectations that Seres Therapeutics Inc. (MCRB) stock would likely to be making an EPS of -$0.47 in the current quarter, while forecast for next quarter EPS is -$0.43 and it is -$1.08 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.55 which is -$0.3 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.72 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 36.00% while it is estimated to increase by 57.30% in next year.
Analysts at 8 brokerage firms have issued recommendations for the Seres Therapeutics Inc. (MCRB)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.90. Out of those 8 Wall Street analysts, 7 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 1 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on July 23, 2021 offering a Sell rating for the stock and assigned a target price range of between $24 and $7 to it. Coverage by Goldman stated Seres Therapeutics Inc. (MCRB) stock as a Neutral in their note to investors on May 18, 2021, suggesting a price target of $24 for the stock. On March 05, 2021, Chardan Capital Markets Upgrade their recommendations, while on September 18, 2020, Chardan Capital Markets Downgrade their ratings for the stock with a price target of $27.50. Stock get an Overweight rating from Piper Sandler on August 18, 2020.